Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics.
10.3779/j.issn.1009-3419.2020.102.24
- Author:
Xinghao AI
1
;
Yong CAI
2
;
Qian CHU
3
;
Chengbo HAN
4
;
You LU
5
;
Songbing QIN
6
;
Lin WU
7
;
Conghua XIE
8
;
Zhiyong YUAN
9
;
Wenzhao ZHONG
10
;
Xiaoxia ZHU
11
;
Joe Y CHANG
12
;
Zhengfei ZHU
13
Author Information
1. Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
2. Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
3. Department of Radiation Oncology, Tongji Hospital, Tongji Medical College, Wuhan 430030, China.
4. Department of Clinical Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China.
5. Department of Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.
6. Department of Radiation Oncology, The First Affiliated Hospital of Suzhou University, Suzhou 215006, China.
7. Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
8. Department of Cancer Radiotherapy and Chemotherapy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
9. Department of Radiation Oncology, Cancer Institute and Hospital, Tianjin Medical University, Tianjin 300060, China.
10. Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou 510080, China.
11. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
12. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston TX 77030, USA.
13. Department of Radiotherapy, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Collective Name:Radiotherapy-Immunotherapy Discussion Group
- Publication Type:Journal Article
- Keywords:
Adverse effects;
Brain metastases;
Immune checkpoint inhibitors;
Immunotherapy;
Mixed responses;
Neoplasms;
Radiotherapy;
Toxicity
- From:
Chinese Journal of Lung Cancer
2020;23(6):532-540
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer death worldwide as well as in China. For many years, conventional oncologic treatments such as surgery, chemotherapy, and radiotherapy (RT) have dominated the field of non-small cell lung cancer (NSCLC). The recent introduction of immunotherapy in clinical practice, led to a paradigm shift in lung cancer as in many other solid tumors. Recent pre-clinical and clinical data have shown RT may also modify antitumor immune responses through induction of immunogenic cell death and reprogramming of the tumor microenvironment. This has led many to reexamine RT as a partner therapy to immuno-oncology treatments and investigate their potential synergy in an exponentially growing number of clinical trials. Clinical trials combining radiotherapy and immunotherapy are attracting major attention, experts were invited to discuss frontier and controversial academic topics: (1) Recent developments of clinical synergy between radiation and immune checkpoint inhibitors (ICIs) in the treatment of NSCLC; (2) Will immunotherapy and radiotherapy increase the toxicity risk for cancer patients; (3) How to cope the mixed responses/disassociated responses phenomenon in checkpoint inhibition therapy to NSCLC with local ablative therapy; (4) Combining radiotherapy and immunotherapy in the treatment of NSCLC brain metastases.
